外科理论与实践 ›› 2023, Vol. 28 ›› Issue (01): 1-6.doi: 10.16139/j.1007-9610.2023.01.01
• 述评 • 下一篇
收稿日期:
2022-12-19
出版日期:
2023-01-25
发布日期:
2023-03-25
通讯作者:
朱正纲
E-mail:zzg1954@hotmail.com
Received:
2022-12-19
Online:
2023-01-25
Published:
2023-03-25
Contact:
ZHU Zhenggang
E-mail:zzg1954@hotmail.com
摘要:
胃癌是国内、外常见恶性肿瘤,手术仍是治疗胃癌的主要方法。一系列临床研究改变了传统胃癌手术理念,避免盲目扩大手术切除范围。腹腔镜手术治疗早期和局部进展期胃癌的疗效并不劣于开腹手术。胃癌微创手术发展的关键是把握合理的手术指征,建立手术技术培训系统,以及优化成本与效益。理性认识胃癌扩大术脏器切除与保留脏器功能的关系。注重局部进展期胃癌围术期治疗的全程管理。并提倡晚期胃癌的术前转化治疗。对广泛转移晚期胃癌的姑息性切除术应慎之又慎,建议综合治疗,旨在延长病人生命。
中图分类号:
朱正纲. 胃癌外科综合治疗的若干进展与展望[J]. 外科理论与实践, 2023, 28(01): 1-6.
ZHU Zhenggang. Progress and prospect of surgical comprehensive treatment of gastric cancer[J]. Journal of Surgery Concepts & Practice, 2023, 28(01): 1-6.
[1] |
HARTGRINK H H, VAN DE VELDE C J, PUTTER H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch Gastric Cancer Group trial[J]. J Clin Oncol, 2004, 22(11):2069-2077.
doi: 10.1200/JCO.2004.08.026 pmid: 15082726 |
[2] |
SONGUN I, PUTTER H, KRANENBARG E M, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial[J]. Lancet Oncol, 2010, 11(5):439-449.
doi: 10.1016/S1470-2045(10)70070-X pmid: 20409751 |
[3] |
SASAKO M, SANO T, YAMAMOTO S, et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomized controlled trial[J]. Lancet Oncol, 2006, 7(8):644-651.
doi: 10.1016/S1470-2045(06)70766-5 URL |
[4] |
SASAKO M, SANO T, YAMAMOTO S, et al. D2 lympha-denectomy alone or with para-aortic nodal dissection for gastric cancer[J]. N Engl J Med, 2008, 359(5):453-462.
doi: 10.1056/NEJMoa0707035 URL |
[5] |
SANO T, SASAKO M, MIZUSAWA J, et al. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma[J]. Ann Surg, 2017, 265(2):277-283.
doi: 10.1097/SLA.0000000000001814 pmid: 27280511 |
[6] |
KUROKAWA Y, DOKI Y, MIZUSAWA J, et al. Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial[J]. Lancet Gastroenterol Hepatol, 2018, 3(7):460-468.
doi: 10.1016/S2468-1253(18)30090-6 URL |
[7] |
KIM H H, HAN S U, KIM M C, et al. Effect of laparoscopic distal gastrectomy vs. open distal gastrectomy on long-term survival among patients with stage Ⅰgastric cancer: the KLASS-01 randomized clinical trial[J]. JAMA Oncol, 2019, 5(4):506-513.
doi: 10.1001/jamaoncol.2018.6727 URL |
[8] |
HYUNG W J, YANG H K, PARK Y K, et al. Long-term outcomes of laparoscopic distal gastrectomy for locally advanced gastric cancer: the KLASS-02-RCT randomized clinical trial[J]. J Clin Oncol, 2020, 38(28):3304-3313.
doi: 10.1200/JCO.20.01210 pmid: 32816629 |
[9] |
KATAI H, MIZUSAWA J, KATAYAMA H, et al. Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage ⅠA or ⅠB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial[J]. Lancet Gastroenterol Hepatol, 2020, 5(2):142-151.
doi: 10.1016/S2468-1253(19)30332-2 URL |
[10] |
YU J, HUANG C, SUN Y, et al. Effect of laparoscopic vs. open distal gastrectomy on 3-year disease-free survival in patients with locally advanced gastric cancer: the CLASS-01 randomized clinical trial[J]. JAMA, 2019, 321(20):1983-1992.
doi: 10.1001/jama.2019.5359 URL |
[11] |
LIU F, HUANG C, XU Z, et al. Morbidity and mortality of laparoscopic vs. open total gastrectomy for clinical stageⅠgastric cancer: the CLASS02 multicenter randomized clinical trial[J]. JAMA Oncol, 2020, 6(10):1590-1597.
doi: 10.1001/jamaoncol.2020.3152 URL |
[12] |
LI Z, SHAN F, YING X, et al. Assessment of laparoscopic distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: a randomized clinical trial[J]. JAMA Surg, 2019, 154 (12):1093-1101.
doi: 10.1001/jamasurg.2019.3473 pmid: 31553463 |
[13] |
CHEN Q Y, XIE J W, ZHONG Q, et al. Safety and efficacy of indocyanine green tracer-guided lymph node dissection during laparoscopic radical gastrectomy in patients with gastric cancer: a randomized clinical trial[J]. JAMA Surg, 2020, 155(4):300-311.
doi: 10.1001/jamasurg.2019.6033 URL |
[14] | 姚学新, 严超, 燕敏, 等. 胃癌D_2根治术联合脾切除与否对疗效影响的比较研究[J]. 中华胃肠外科杂志, 2010, 13(2):111-114. |
YAO X X, YAN C, YAN M, et al. A comparative study on the efficacy of spleen-preserving modified D_2 radical gastrectomy and D_2 radical gastrectomy with splenectomy[J]. Chin J Gastrointest Surg, 2010, 13(2):111-114. | |
[15] | 何晓生, 吴小剑, 汪建平, 等. 胃癌根治术腹主动脉旁淋巴结清扫安全性与有效性的Meta分析[J]. 中华胃肠外科杂志, 2010, 13(2):119-124. |
HE X S, WU X J, WANG J P, et al. Meta-analysis of safety and efficacy on paraaortic lymphadenectomy in gastric cancer[J]. Chin J Gastrointest Surg, 2010, 13(2):119-124. | |
[16] |
NAUM C, BÎRLĂ R, MARICA D C, et al. In search of the optimal reconstruction method after total gastrectomy. is Roux-en-Y the best? A review of the randomized clinical trials[J]. Chirurgia, 2020, 115(1):12-22.
doi: 10.21614/chirurgia.115.1.12 URL |
[17] |
ZHAO L, LING R, CHEN J, et al. Clinical outcomes of proximal gastrectomy versus total gastrectomy for proximal gastric cancer: a systematic review and meta-analysis[J]. Dig Surg, 2021, 38(1):1-13.
doi: 10.1159/000506104 URL |
[18] |
CUNNINGHAM D, ALLUM W H, STENNING S P, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J]. N Engl J Med, 2006, 355(1):11-20.
doi: 10.1056/NEJMoa055531 URL |
[19] | YCHOU M, BOIGE V, PIGNON J P, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phaseⅢtrial[J]. J Clin Oncol, 2011, 29(13):1715-1721. |
[20] |
AL-BATRAN S E, HOMANN N, PAULIGK C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial[J]. Lancet, 2019, 393(10184):1948-1957.
doi: 10.1016/S0140-6736(18)32557-1 URL |
[21] |
KANG Y K, YOOK J H, PARK Y K, et al. PRODIGY: a phase Ⅲ study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer[J]. J Clin Oncol, 2021, 39(26):2903-2913.
doi: 10.1200/JCO.20.02914 URL |
[22] |
ZHANG X, LIANG H, LI Z, et al. Perioperative or post-operative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial[J]. Lancet Oncol, 2021, 22(8):1081-1092.
doi: 10.1016/S1470-2045(21)00297-7 URL |
[23] | 丁学伟, 郑志超, 赵群, 等. 基于多中心真实世界数据的胃癌围手术期化疗患者生存分析[J]. 中华胃肠外科杂志, 2021, 24(5):403-412. |
DING X W, ZHENG Z C, ZHAO Q, et al. A multi-center retrospective study of perioperative chemotherapy for gastric cancer based on real-world data[J]. Chin J Gastrointest Surg, 2021, 24(5):403-412. | |
[24] | WANG F H, ZHANG X T, LI Y F, et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021[J]. Cancer Commun (Lond), 2021, 41(8):747-795. |
[25] |
GAO X, ZHANG Y, YUAN F, et al. Locally advanced gastric cancer: total iodine uptake to predict the response of primary lesion to neoadjuvant chemotherapy[J]. J Cancer Res Clin Oncol, 2018, 144(11):2207-2218.
doi: 10.1007/s00432-018-2728-z pmid: 30094537 |
[26] |
ZHANG Y, CHEN J, YUAN F, et al. Prognostic role of iodine values for gastric cancer after neoadjuvant chemotherapy: a strong independent prognostic factor[J]. Diagn Interv Radiol, 2022, 28(5):388-395.
doi: 10.5152/dir URL |
[27] |
CHEN Y, YUAN F, WANG L, et al. Evaluation of dual-energy CT derived radiomics signatures in predicting outcomes in patients with advanced gastric cancer after neoadjuvant chemotherapy[J]. Eur J Surg Oncol, 2022, 48(2):339-347.
doi: 10.1016/j.ejso.2021.07.014 URL |
[28] |
CHEN Y, XU W, LI Y L, et al. CT-based radiomics showing generalization to predict tumor regression grade for advanced gastric cancer treated with neoadjuvant chemotherapy[J]. Front Oncol, 2022, 12:758863.
doi: 10.3389/fonc.2022.758863 URL |
[29] |
YOSHIDA K, YAMAGUCHI K, OKUMURA N, et al. Is conversion therapy possible in stage Ⅳ gastric cancer: the proposal of new biological categories of classification[J]. Gastric Cancer, 2016, 19(2):329-338.
doi: 10.1007/s10120-015-0575-z URL |
[30] | 朱正纲. 晚期胃癌转化治疗的理念与临床意义[J]. 外科理论与实践, 2017, 22(1):1-4. |
ZHU Z G. Concept and clinical significance of conversion therapy for unresectable advanced gastric cancer[J]. J Surg Concepts Pract, 2017, 22(1):1-4. | |
[31] | 朱正纲. 晚期胃癌转化治疗的难点、焦点与要点[J]. 外科理论与实践, 2019, 24(1):1-5. |
ZHU Z G. The difficulty and some focal points in conversion therapy for patients with far-advanced gastric cancer[J]. J Surg Concepts Pract, 2019, 24(1):1-5. | |
[32] |
HANAHAN D. Hallmarks of cancer: new dimensions[J]. Cancer Discov, 2022, 12(1):31-46.
doi: 10.1158/2159-8290.CD-21-1059 pmid: 35022204 |
[33] |
YOSHIKAWA T, SASAKO M, YAMAMOTO S, et al. Phase Ⅱ study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer[J]. Br J Surg, 2009, 96(9):1015-1022.
doi: 10.1002/bjs.6665 URL |
[34] |
TSUBURAYA A, MIZUSAWA J, TANAKA Y, et al. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis[J]. Br J Surg, 2014, 101(6):653-660.
doi: 10.1002/bjs.9484 pmid: 24668391 |
[35] | ZHANG K, CHEN L. Chinese consensus on the diagnosis and treatment of gastric cancer with liver metastases[J]. Ther Adv Med Oncol, 2020, 12: 1758835920904803 |
[36] | 程向东, 季加孚. 胃癌卵巢转移诊断和治疗中国专家共识(2021版)[J]. 中国肿瘤, 2022, 31(2):81-87. |
CHENG X D, JI J F. The Chinese expert consensus on the diagnosis and treatment of ovarian metastasis from gastric cancer,2021[J]. China Cancer, 2022, 31(2):81-87. | |
[37] |
ISHIGAMI H, FUJIWARA Y, FUKUSHIMA R, et al. Phase Ⅲ trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX GC trial[J]. J Clin Oncol, 2018, 36(19):1922-1929.
doi: 10.1200/JCO.2018.77.8613 URL |
[38] |
YANG Z Y, YUAN F, LU S, et al. Efficacy and safety of conversion therapy by intraperitoneal and intravenous paclitaxel plus oral S-1 in gastric cancer patients with peritoneal metastasis: a prospective phase Ⅱ study[J]. Front Oncol, 2022, 12:905922.
doi: 10.3389/fonc.2022.905922 URL |
[39] | 朱正纲. 胃癌腹膜转移转化性治疗的临床意义与实践要点[J]. 中华胃肠外科杂志, 2017, 20(10):1094-1098. |
ZHU Z G. Clinical significance and practice points of conversion therapy for gastric cancer with peritoneal metastasis[J]. Chin J Gastrointest Surg, 2017, 20(10):1094-1098. | |
[40] | 朱正纲. 预防与治疗胃癌腹膜转移的若干关键问题[J]. 外科理论与实践, 2021, 26(1):1-6. |
ZHU Z G. Key issues in prevention and treatment of peritoneal metastatic gastric cancer[J]. J Surg Concepts Pract, 2021, 26(1):1-6. |
[1] | 赵法之, 赵平. 胃癌治疗手术中心论体系的形成与完善[J]. 外科理论与实践, 2023, 28(01): 24-30. |
[2] | 李国立, 郭飞龙. 动静脉结合术前化疗在进展期胃癌治疗中的应用[J]. 外科理论与实践, 2023, 28(01): 31-35. |
[3] | 刘文韬, 刘福坤. 中国胃癌围术期综合治疗概述与展望[J]. 外科理论与实践, 2023, 28(01): 36-41. |
[4] | 张欢, 陈勇. 影像组学在胃癌诊断中的新进展[J]. 外科理论与实践, 2023, 28(01): 42-48. |
[5] | 邓仕杰, 袁菲. EB病毒阳性的胃癌与伴有淋巴样间质的胃癌——诊断及分子检测进展[J]. 外科理论与实践, 2023, 28(01): 53-57. |
[6] | 李建芳, 余俊贤, 严超, 朱正纲, 刘炳亚. 胃癌基础与转化研究的热点问题[J]. 外科理论与实践, 2023, 28(01): 7-16. |
[7] | 卢一鸣, 熊建平, 田艳涛. 晚期胃癌转化治疗的发展现状与研究前景[J]. 外科理论与实践, 2023, 28(01): 17-23. |
[8] | 陈平, 徐莹, 吴云林. 消化内镜在早期胃癌诊断中的应用进展[J]. 诊断学理论与实践, 2022, 21(05): 551-554. |
[9] | 王亚雷. 重视胃癌高危人群的内镜精查[J]. 诊断学理论与实践, 2022, 21(05): 555-559. |
[10] | 马乾宸, 张本炎, 芮炜玮, 王婷, 罗方秀, 王朝夫, 袁菲. 中国3 071例胃癌病理分型分析[J]. 诊断学理论与实践, 2022, 21(05): 560-566. |
[11] | 杨蕊馨, 杜宇童, 燕然林, 朱正纲, 李琛, 于颖彦. 消化道肿瘤单细胞转录组测序研究中生物样本前处理改良的探索[J]. 诊断学理论与实践, 2022, 21(05): 567-574. |
[12] | 陈益定, 吴世杰. 遗传性乳腺癌外科治疗[J]. 外科理论与实践, 2022, 27(05): 392-395. |
[13] | 戴志强, 郑金鑫, 唐兆庆, 张启, 顾远, 史忠义, 胡国华, 孙益红. 淋巴结转移率对Ⅱ~Ⅲ期胃癌根治术后病人预后的评估[J]. 外科理论与实践, 2022, 27(05): 429-434. |
[14] | 张吉祥, 谢智华, 综述, 李炜, 姜小清, 审校. 肝内胆管癌的分型和外科治疗热点[J]. 外科理论与实践, 2022, 27(05): 478-482. |
[15] | 鲍萍萍, 吴春晓, 顾凯, 庞怡, 王春芳, 施亮, 向詠梅, 龚杨明, 窦剑明, 吴梦吟, 付晨, 施燕. 上海市2016年胃癌发病特征及2002年至2016年胃癌发病趋势分析[J]. 诊断学理论与实践, 2022, 21(04): 462-469. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||